Live webinar from Singapore: Portfolio analysis - Choosing your communication strategy
Tuesday 1st October 2019 16:00SGT/ 16:00CST/ 17:00JST
Portfolio Analysis and Optimization concentrates on determining the impact that multiple assets have within therapeutic categories, and how the marketing of these assets impacts on overall strategy. This is an important tool for pharmaceutical companies in today’s market. As they simultaneously develop multiple products that can become extremely costly, portfolio management to improve decision-making can have a significant impact on the bottom line. At its very core, it is about selecting how to allocate resources and marketing efforts across multiple assets.
How to conduct an effective epidemiological data review
Clients often ask us if we can triangulate various data sources to fully understand the opportunity for an asset. There are clear benefits - combining primary market research findings with existing data sets provides validity and depth, whilst eliminating many inconsistencies, which helps guide the direction for future marketing strategy and initiatives.
MRX time machine: How to use time series forecasting to improve your demand assessment
In the second part of our Innovation in #MRX series we demonstrate how to use time series forecasting to better inform product uptake and competitive scenarios up to 10 years into the future.
Understanding likely demand for a new product or service is essential to help develop the right brand strategy. Techniques such as conjoint and fixed product profile assessments are great for evaluating the market landscape and opportunity, but are they enough? Can we predict the future with greater accuracy? Time series forecasting is one of the latest market research innovations we have been championing at Research Partnership and we would like to share the benefits of this technique with you.
How we used a hybrid qual-quant methodology to assess the market opportunity for a new rare disease treatment
Our client is a recently established independent biopharmaceutical company specialising in small molecule development. They were developing a new oral compound for the treatment of a rare genetic disease for which the standard treatment is administered intravenously, however a large proportion of patients receive monitoring only or remain undiagnosed. Their objective was to successfully launch their product in order to provide clinically meaningful benefits to patients and contribute to the overall growth of their business.
Research Partnership welcomes Misti Paul as Analytics Director
Research Partnership is pleased to welcome Misti Paul, who recently joined the company as Analytics Director.
Misti has over 16 years’ experience in statistical modeling and market research. Before joining Research Partnership, Misti headed up her own advanced statistical consultancy firm Advanced Analytics, providing statistical modeling and consulting services to global pharmaceutical, biotech and medical device companies. She specialised in the areas of merger and acquisition modelling, segmentation, new product development, conjoint methodologies and other analytical techniques.